280 - Diffuse Large B Cell Lymphoma (DLBCL)

Request Details:

Date Submitted: 01/08/2022

Q1. Does your trust treat patients with Diffuse Large B Cell Lymphoma (DLBCL)? If not, then which trust do you refer DLBCL patients to? Yes
Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL)? From 14/01/2022 – 14/07/2022 - 40
Q3. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:
• R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
• R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
• Other immuno-chemotherapy
• Other chemotherapy
• Stem cell transplant or bone marrow transplant (autologous or allogeneic)
• Pola-BR (polatuzumab vedotin with rituximab and bendamustine) - any line of treatment
• Pola-BR (polatuzumab vedotin with rituximab and bendamustine) - third-line treatment only
• Tisagenlecleucel
• Axicabtegene ciloleucel
• Lisocabtagene maraleucel

We collate the SACT data as mandated by Public Health England (PHE) and submit 2 month in arrears, due to time taken to curate these data.
The Trust is withholding the information requested under Section 21 of the Freedom of Information Act, as the information that can be generated is publicly available via PHE.

Q4. In the last 6 months, how many Diffuse Large B Cell Lymphoma (DLBCL) patients have you referred to other trusts for:
• Stem cell transplant or bone marrow transplant (autologous or allogeneic)
• CAR-T therapy (Tisagenlecleucel, Axicabtegene ciloleucel, Lisocabtagene maraleucel)

None. We are a tertiary center so cancer patients are referred to us.

Q5. Do you participate in any active clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL)? If so, can you please provide the name of each trial along with the number of patients taking part? The Trust is unable to share the number of patients taking part under Section 41 as the information requested relates to the Clinical Trials Agreement which contains confidentiality terms.

Last updated: September 2022